Keywordsantibiotics; primary care; antimicrobial resistance; urinary tract infection; nitrofurantoin; urinary tract infection; therapeutic use; biofilm; Pseudomonas aeruginosa; zinc sulfate; urinary tract infection; fluoroquinolone; synergism; urinary tract infection; catheter; ureteral stent; urinary tract infection; female; cystitis; pyelonephritis; azithromycin; extended release; urethritis; Neisseria gonorrhoeae; Chlamydia trachomatis; Mycoplasma genitalium; Ureaplasma urealyticum; urogenital; infection; tuberculosis; epidemiology; diagnosis; therapy; acute uncomplicated cystitis; cranberry; A2-type proanthocyanidins; P. mirabilis; E. coli; prostatitis; clinical; general practitioner; network; ambulatory; ciprofloxacin; trimethoprim-sulfamethoxazole; nitrofurantoin; susceptibility; bacterial resistance; E. coli; urinary cultures; urinary tract infection; antimicrobial stewardship; antimicrobial resistance; UTI; urinary tract infections; antibiotics; duration; appropriate; uUTI; antibiotic resistance; fluoroquinolone; β-lactam; n/a
